Vaccine and anti-viral drug development for SARS-CoV2

Guest Editor

Prof. Sang Heui Seo
College of Veterinary Medicine, Chungnam National University, Daejeon, South Korea
seos@cnu.ac.kr

Message from the Guest Editor

Dear Colleagues,

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) known as covid-19 still causes tremendous burden on humans. This virus has many variants such as Alpha, Beta, Gamma and Delta. Some variants have the potential for the increased transmissibility, increased virulence, or reduced effectiveness of vaccines against current vaccines.

We need to develop better vaccine for protecting people from being infected from emerging variants SARS-CoV2 and anti-viral drugs to treat humans infected with SARS-CoV2. The goal of this special issue is to publish new approach to vaccines and anti-viral drugs for SARS-CoV2. Interesting researchers are encouraged to submit short reports, and full papers based on animal studies and human clinical trials.

Prof. Sang Heui Seo
Guest Editor

Submission Deadline: 31 May 2022
Submission: https://www.fbscience.com/Landmark
Science Citation Index Expanded: 4.009 (2020)
Contact us: Front.Biosci.Landmark@fbscience.com